Aliskiren combined with other inhibitors of the renin-angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.
|Original language||English (US)|
|Number of pages||2|
|Journal||Nature Reviews Nephrology|
|State||Published - May 1 2012|
ASJC Scopus subject areas